To ensure the accessibility of immunotherapy to advanced cancer patients, for which the diagnostic material is often represented by small tissue samples, many efforts have been performed to implement and validate PD‐L1 IHC scoring on cytological material, such as in non–small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and lung cancer.